Indication: For the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. Loperamide hydrochloride is also indicated for reducing the volume of discharge from ileostomies.
Pharmacology: Loperamide is a synthetic anti-diarrheal indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. Loperamide is also indicated for reducing the volume of discharge from ileostomies. In man, Loperamide prolongs the transit time of the intestinal contents. It reduces the daily fecal volume, increases the viscosity and bulk density, and diminishes the loss of fluid and electrolytes. Tolerance to the antidiarrheal effect has not been observed. Loperamide is an opioid receptor agonist and acts on the mu opioid receptors in the myenteric plexus large intestines; it does not affect the central nervous system like other opioids. It works specifically by decreasing the activity of the myenteric plexus which decreases the motility of the circular and longitudinal smooth muscles of the intestinal wall. This increases the amount of time substances stay in the intestine, allowing for more water to be absorbed out of the fecal matter. Loperamide also decreases colonic mass movements and suppresses the gastrocolic reflex
Mechanism Of Action: in vitro and animal studies show that Loperamide acts by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. Loperamide inhibits peristaltic activity by a direct effect on the circular and longitudinal muscles of the intestinal wall. It is a non-selective calcium channel blocker and binds to opioid mu-receptors. Evidence also suggests that at higher concentrations it binds to NMDA receptors and to calmodulin
Drug Category: Antidiarrheals; Antidiarrheals; ATC:A07DA03; ATC:A07DA05
Absorption: Not well absorbed from gastrointestinal tract
Interactions:
DrugBank: Interactions for Loperamide
Interactions for Loperamide:
There was no evidence in clinical trials of drug interactions with concurrent medications.
Chemical IUPAC Name: 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide
Chemical Formula: C29H33ClN2O2
Half Life: 10.8 hours (9.1-14.4 hours)
Drug Type: Approved Drug
# Accession No: APRD00275
CAS Registry Number: 53179-11-6
Loperamide News (When available)
Johnson & Johnson inks multi-year sponsorship with FLW OutdoorsJan 10, 2006 Indiantelevision.com, MUMBAI: FLW Outdoors and Johnson & Johnson (J&J) have signed a multi-year sponsorship deal, wherein the latter will promote their Imodium Advanced, Pepcid ...
Johnson & Johnson Inks Multiyear Sponsorship with FLW OutdoorsJan 9, 2006 Yahoo! News (press release) In 2006, Johnson & Johnson will promote their Imodium Advanced®, Pepcid Complete®, Tylenol Extra Strength Rapid Release® and Tylenol Severe Allergy® brands ...
Johnson & Johnson Inks Multiyear Sponsorship with FLW OutdoorsJan 9, 2006 PR Newswire (press release), In 2006, Johnson & Johnson will promote their Imodium Advanced(R), Pepcid Complete(R), Tylenol Extra Strength Rapid Release(R) and Tylenol Severe Allergy(R ...
Diet, medicines ease diarrheaJan 13, 2006 Sun-Sentinel.com, ...medicines can help. Imodium, a commonly used antidiarrhea medicine, can often control bile-induced diarrhea. Questran and WelChol ...
USA. Johnson & Johnson signs multiyear sponsorship with FLW ...Jan 10, 2006 BYM News (press release), In 2006, Johnson & Johnson will promote their Imodium Advanced, Pepcid Complete, Tylenol Extra Strength Rapid Release and Tylenol Severe Allergy brands through ...
OFF THE RECORDDec 29, 2005 Glasgow Daily Record, ...to how to cook massive, artery-furring meals, featuring an enormous fowl, in the certain knowledge that getting it wrong could mean a week on the Imodium diet. ...
Newtown NotesJan 5, 2006 Danbury News Times, Stamford Safari. The same year she designed a faux stained glass porta-potty for Imodium's "Urban Relief Project" in NYC. Currently ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
